Skip to main content

Veeva Systems Inc. (VEEV) Stock Analysis

Recovery setup · Catalyst-Driven edge

HoldDEATH CROSS (EXEMPT)Moderate Confidence

Healthcare · Health Information Services

Hold if already holding. Not a fresh buy at $163.57, but acceptable to hold if already in. Reasons: Concentration risk — Customer: life sciences industry; Leverage penalty (D/E 1.3): -0.5.

Veeva provides cloud software, data, and business consulting exclusively for the global life sciences industry across R&D, quality, and commercial functions for 1,552 customers as of January 2026. Revenue is primarily subscription-based; top 10 customers accounted for 28% of... Read more

$163.57+44.8% A.UpsideScore 6.2/10#2 of 13 Health Information Services
QualityF-score8 / 9FCF yield3.92%
Stop $151.88Target $236.41(analyst − 10%)A.R:R 5.4:1
Analyst target$262.68+60.6%28 analysts
$236.41our TP
$163.57price
$262.68mean
$350

Hold if already holding. Not a fresh buy at $163.57, but acceptable to hold if already in. Reasons: Concentration risk — Customer: life sciences industry; Leverage penalty (D/E 1.3): -0.5. Chart setup: Death cross but MACD improving, RSI 55. Maintain position. Not compelling to add more. Score 6.2/10, moderate confidence.

Passes 9/10 gates (positive momentum, favorable risk/reward ratio, clean insider activity, positive momentum, no SEC red flags, news events none recent, earnings proximity 15d clear, semi cycle peak clear, materials cycle peak clear). Suitability: moderate.

Recent Developments — Veeva Systems Inc.

Generated 2026-05-20T21:06:21Z.

Thesis

Rewards
V7 quality resilience bonus: +0.2 (Q=7.9 in RISK_OFF)
Sector modifier (Healthcare): +0.5
Strong earnings beat streak (4/4)
Risks
Concentration risk — Customer: life sciences industry
Leverage penalty (D/E 1.3): -0.5
Below 200-MA, MA slope -7.3%/30d (confirmed downtrend)

Key Metrics

P/E (TTM)30.1
P/E (Fwd)16.6
Mkt Cap$26.7B
EV/EBITDA20.6
Profit Mgn28.4%
ROE13.9%
Rev Growth16.0%
Beta0.92
DividendNone
Rating analysts38

Quality Signals

Piotroski F8/9MoatNarrow

Options Flow

P/C1.23bearish
IV66%elevated

Concentration Risks(10-K Item 1A)

  • MEDIUMCustomertop 10 customers28%
    10-K Item 1A: 'our top 10 customers accounted for 28% of our total revenues'
  • MEDIUMGeographiccustomers outside North America40%
    10-K Item 1A: 'customers outside North America accounted for approximately 40% of our total revenues'
  • HIGHCustomerlife sciences industry
    10-K Item 1A: 'Nearly all of our revenues are generated by sales to customers in the life sciences industry'

Material Events(8-K, last 90d)

  • 2026-04-20Item 5.02LOW
    Josh Faddis, SVP General Counsel, announced retirement effective November 1, 2026; will transition to part-time advisor. Veeva will appoint a successor upon his transition. No disagreement cited.
    SEC filing →

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer

Rating Breakdown

1 floor-breaker

Technicals below the gate floor. Component breakdown shows what dragged the score down.static

52w Position
0.5
Bollinger
4.5
Support Resistance
5.2
GatesDeath cross exempted (quality + momentum high enough)Momentum 5.8>=5.5A.R:R 5.4 ≥ 1.5Insider activity: OKNo SEC red flagsNEWS EVENTS NONE RECENTEARNINGS PROXIMITY 15d clearSEMI CYCLE PEAK CLEARMATERIALS CYCLE PEAK CLEARRecoverySuitability: Moderate
RSI
55 · Neutral
20D MA 50D MA 200D MADEATH CROSSSupport $152.30Resistance $175.11

Price Targets

$152
$236
A.Upside+44.5%
A.R:R5.4:1

Position Sizing

ConvictionNone
Suggested %0.5%
Max %1%
RegimeRisk-Off

Analyst Consensus

Analysts38
Consensus4.0/5
Avg Target$263

Earnings

B
B
B
B
4/4 beats
Next Earnings2026-06-03 (15d)

Verdict History

reverse chrono — latest first
Loading history...
Verdicts are recorded on every nightly pipeline run. Rows capture transitions (verdict flips, score deltas ≥0.3, entry/TP/SL changes). Rows with a ▶ can be expanded to see the change reason. Aggregate cohort performance is tracked in the recommendation ledger.
Frequently Asked Questions
Is VEEV stock a buy right now?

Hold if already holding. Not a fresh buy at $163.57, but acceptable to hold if already in. Reasons: Concentration risk — Customer: life sciences industry; Leverage penalty (D/E 1.3): -0.5. Chart setup: Death cross but MACD improving, RSI 55. Maintain position. Not compelling to add more. Target $236.41 (+44.5%), stop $151.88 (−7.7%), A.R:R 5.4:1. Score 6.2/10, moderate confidence.

What is the VEEV stock price target?

Take-profit target: $236.41 (+44.8% upside). Target $236.41 (+44.5%), stop $151.88 (−7.7%), A.R:R 5.4:1. Stop-loss: $151.88.

What are the risks of investing in VEEV?

Concentration risk — Customer: life sciences industry; Leverage penalty (D/E 1.3): -0.5; Below 200-MA, MA slope -7.3%/30d (confirmed downtrend).

Is VEEV overvalued or undervalued?

Veeva Systems Inc. trades at a P/E of 30.1 (forward 16.6). TrendMatrix value score: 6.2/10. Verdict: Hold.

What do analysts say about VEEV?

38 analysts cover VEEV with a consensus score of 4.0/5. Average price target: $263.

What does Veeva Systems Inc. do?Veeva provides cloud software, data, and business consulting exclusively for the global life sciences industry across...

Veeva provides cloud software, data, and business consulting exclusively for the global life sciences industry across R&D, quality, and commercial functions for 1,552 customers as of January 2026. Revenue is primarily subscription-based; top 10 customers accounted for 28% of total revenues across fiscal years ended January 2026, 2025, and 2024. Non-North America customers were approximately 40% of fiscal 2026 revenues.

Related stocks: WAY (Waystar Holding Corp.) · HNGE (Hinge Health, Inc.) · HQY (HealthEquity, Inc.) · PRVA (Privia Health Group, Inc.) · MMED (MiniMed Group, Inc.)